Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Sphingolipids as multifaceted mediators in ovarian cancer
Author: Pitman, M.
Oehler, M.K.
Pitson, S.M.
Citation: Cellular Signalling, 2021; 81:1-18
Publisher: Elsevier
Issue Date: 2021
ISSN: 0898-6568
Statement of
Melissa R Pitman, Martin K.Oehler, Stuart M.Pitson
Abstract: Ovarian cancer is the most lethal gynaecological malignancy. It is commonly diagnosed at advanced stage when it has metastasised to the abdominal cavity and treatment becomes very challenging. While current standard therapy involving debulking surgery and platinum + taxane-based chemotherapy is associated with high response rates initially, the large majority of patients relapse and ultimately succumb to chemotherapy-resistant disease. In order to improve survival novel strategies for early detection and therapeutics against treatment-refractory disease are urgently needed. A promising new target against ovarian cancer is the sphingolipid pathway which is commonly hijacked in cancer to support cell proliferation and survival and has been shown to promote chemoresistance and metastasis in a wide range of malignant neoplasms. In particular, the sphingosine kinase 1-sphingosine 1-phosphate receptor 1 axis has been shown to be altered in ovarian cancer in multiple ways and therefore represents an attractive therapeutic target. Here we review the roles of sphingolipids in ovarian cancer progression, metastasis and chemoresistance, highlighting novel strategies to target this pathway that represent potential avenues to improve patient survival.
Keywords: Apoptosis
Ovarian cancer
Rights: © 2021 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.cellsig.2021.109949
Grant ID:
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.